AbbVie to Record $4 Billion Impairment on Stemcentrx Assets

The company will book a roughly $4 billion charge in connection with a 2016 acquisition that it billed as offering a promising cancer treatment.

from WSJ.com: US Business https://on.wsj.com/2F74UrX
via IFTTT